CAS:129101-54-8Rivastigmine tartrate

您的位置 : 首页 / Neuronal Signaling / AChR / Rivastigmine Tartrate

Rivastigmine Tartrate 酒石酸卡巴拉汀 Cat No. FB09072Cas No. 129101-54-8

Synonyms: ENA 713 Tartrate;SDZ-ENA-713 Tartrate

Rivastigmine tartrate is an AchR inhibitor use for treatment of mild to moderate Alzheimer's disease and Parkinson's disease with elimination half-life of ‎1.5 hours.

规格	价格	促销价格	库存

18817579266

立即询价

咨询

18817579266

立即询价

实验数据

储存液制备
- 1 mg
- 5 mg
- 10 mg
- 1 mM
- 2.4974 mL
- 12.4868 mL
- 24.9736 mL
- 5 mM
- 0.4995 mL
- 2.4974 mL
- 4.9947 mL
- 10 mM
- 0.2497 mL
- 1.2487 mL
- 2.4974 mL
计算器摩尔计算器总药量计算器工作液计算器

技术信息

CAS号

129101-54-8

储存条件

粉末: -20°C 3 年

液体: -80°C 12 月

分子式

C18H28N2O8

运输

蓝冰

分子量

400.42

别名

ENA 713 Tartrate;SDZ-ENA-713 Tartrate

溶解度

DMSO	42.0 mg/mL (104.9 mM)
Ethanol	80.0 mg/mL (199.8 mM)

动物实验配方

靶点数据

生物活性

靶点 AChE

IC50:4.15µM BuChE

IC50:37nM
描述Rivastigmine tartrate, a cholinesterase inhibitor (IC₅₀= 5.5 μM), inhibits both butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE). Rivastigmine (0.6 mg/kg intraperitoneally [i.p.]) inhibited AChE and BuChE by 40% and 25%, respectively. Both preclinical studies and studies in human volunteers have shown that rivastigmine induces substantially greater inhibition of AChE in the central nervous system compartment than in the periphery. Moreover, Rivastigmine can modify the levels of several shedding proteins and directs APP processing toward the non-amyloidogenic pathway for Alzheimer's disease.

靶点	Description	IC50
AChE		IC50:4.15µM
BuChE		IC50:37nM